Title :

Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the response assessment in neuro-oncology patient-reported outcome (rano-pro) initiative

Author(s) :

Dirven, Linda [Auteur]
Leiden University Medical Center [LUMC]
Vos, Maartje E. [Auteur]
Walbert, Tobias [Auteur]
University of Michigan [Dearborn]
Armstrong, Terri S. [Auteur]
Arons, David [Auteur]
Van Den Bent, Martin J. [Auteur]
Blakeley, Jaishri O. [Auteur]
Brown, Paul D. [Auteur]
Bulbeck, Helen J. [Auteur]
Chang, Susan M. [Auteur]
Coens, Corneel [Auteur]
Gilbert, Mark R. [Auteur]
Grant, Robin [Auteur]
Jalali, Rakesh [Auteur]
Leach, Danielle [Auteur]
Leeper, Heather [Auteur]
Mendoza, Tito [Auteur]
Nayak, Lakshmi [Auteur]
Oliver, Kathy [Auteur]
Reijneveld, Jaap C. [Auteur]
Le Rhun, Emilie [Auteur]
Universität Zürich [Zürich] = University of Zurich [UZH]
Rubinstein, Larry [Auteur]
Weller, Michael [Auteur]
Wen, Patrick Y. [Auteur]
Taphoorn, Martin J. B. [Auteur]

Journal title :

Neuro-Oncology Practice

Abbreviated title :

Neurooncol Pract

Volume number :

8

Pages :

417-425

Publication date :

2021-08-01

ISSN :

2054-2577

Keyword(s) :

health-related quality of life
patient-reported outcome
symptoms
brain tumor
activities of daily living

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of ...
Show more >The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify PRO measures that have been used in brain tumor studies to date. METHODS: A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis. RESULTS: A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies. The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as instruments designed for other indications or multi- or single-item study-specific questionnaires. The most frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br (n = 167), however, the majority of the instruments were used only once or twice (150/215). CONCLUSION: Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit good content validity and other measurement properties for use in brain tumor patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

INSERM
Université de Lille

Collections :

• Autres travaux scientifiques

Submission date :

2022-06-15T14:00:23Z
2023-04-05T08:55:48Z